Recurrent and de novo malignancies following liver transplantation

Diagnostic Histopathology

Volumn 18, Issue 7, 2012, Pages 290-296

  Fischer, Sandra E ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

De novo malignancy; Hepatocellular carcinoma; Liver transplantation; Post transplant malignancies

Indexed keywords

ALCOHOL; BIOLOGICAL MARKER; CYCLOSPORIN; RAPAMYCIN; STEROID; TACROLIMUS;

AGE; ARTICLE; BILE DUCT CARCINOMA; CANCER SCREENING; CELL CYCLE PROGRESSION; COLON RESECTION; COLORECTAL CANCER; DEATH; DRUG WITHDRAWAL; ENTERITIS; GENE MUTATION; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; HEMANGIOENDOTHELIOMA; HEPATOBLASTOMA; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INCIDENCE; INFECTIOUS DIARRHEA; INTERNAL HERNIA; INTESTINE ISCHEMIA; INTESTINE OBSTRUCTION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER RESECTION; LIVER TRANSPLANTATION; RECURRENT CANCER; SMOKING; SUN EXPOSURE; TUMOR RECURRENCE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VOLVULUS;

EID: 84864765973     PISSN: 17562317     EISSN: 18767621     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2012.07.001     Document Type: Article

References (47)

1. Hertl M., Cosimi A.B. Liver transplantation for malignancy. Oncologist 2005, 10:269-281.
2. Grossman E.J., Millis J.M. Liver transplantation for non-hepatocellular carcinoma malignancy: indications, limitations, and analysis of the current literature. Liver Transpl 2010, 16:930-942.
3. Koschny R., Schmidt J., Ganten T.M. Beyond Milan criteria - chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis. Clin Transplant 2009, 23(suppl 21):49-60.
4. Mazzaferro V., Chun Y.S., Poon R.T., et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2008, 15:1001-1007.
5. Alsina A.E. Liver transplantation for hepatocellular carcinoma. Cancer Control 2010, 17:83-86.
6. Silva M.F., Wigg A.J. Current controversies surrounding liver transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol 2010, 25:1217-1226.
7. Hanje A.J., Yao F.Y. Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transpl 2008, 13:234-240.
8. Yao F.Y. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008, 8:1982-1989.
9. Sandhu L., Sandroussi C., Guba M., et al. Live donor versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl 2012, 18:315-322.
10. Toso C., Trotter J., Wei A., et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008, 14:1107-1115.
11. Sandroussi C., Dawson L.A., Lee M., et al. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl Int 2010, 23:299-306.
12. Zimmerman M.A., Ghobrial R.M., Tong M.J., et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008, 143:182-188.
13. Shirabe K., Itoh S., Yoshizumi T., et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 2007, 95:235-240.
14. Guba M., von B.P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-135.
15. Toso C., Merani S., Bigam D.L., Shapiro A.M., Kneteman N.M. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010, 51:1237-1243.
16. Patel T. Cholangiocarcinoma - controversies and challenges. Nat Rev Gastroenterol Hepatol 2011, 8:189-200.
17. Meza-Junco J., Montano-Loza A.J., Ma M., Wong W., Sawyer M.B., Bain V.G. Cholangiocarcinoma: has there been any progress?. Can J Gastroenterol 2010, 24:52-57.
18. Heimbach J.K., Gores G.J., Nagorney D.M., Rosen C.B. Liver transplantation for perihilar cholangiocarcinoma after aggressive neoadjuvant therapy: a new paradigm for liver and biliary malignancies?. Surgery 2006, 140:331-334.
19. Finegold M.J., Egler R.A., Goss J.A., et al. Liver tumors: pediatric population. Liver Transpl 2008, 14:1545-1556.
20. Gedaly R., Daily M.F., Davenport D., et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg 2011, 146:953-958.
21. Benten D., Sterneck M., Panse J., Rogiers X., Lohse A.W. Low recurrence of preexisting extrahepatic malignancies after liver transplantation. Liver Transpl 2008, 14:789-798.
22. Jain A., Fiaz O., Sheikh B., et al. Recurrent nonhepatic and de novo malignancies after liver transplantation. Transplantation 2009, 88:706-710.
23. Chak E., Saab S. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int 2010, 30:1247-1258.
24. Herrero J.I. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl 2009, 15(suppl 2):S90-S94.
25. Zafar S.Y., Howell D.N., Gockerman J.P. Malignancy after solid organ transplantation: an overview. Oncologist 2008, 13:769-778.
26. Herrero A.J. Screening of de novo tumors after liver transplantation. J Gastroenterol Hepatol 2012, 27:1011-1016.
27. Washington K. Update on post-liver transplantation infections, malignancies, and surgical complications. Adv Anat Pathol 2005, 12:221-226.
28. Monaco A.P. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009, 87:157-163.
29. Martinez O.M., de Gruijl F.R. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant 2008, 8:2205-2211.
30. Nishihori T., Strazzabosco M., Saif M.W. Incidence and management of colorectal cancer in liver transplant recipients. Clin Colorectal Cancer 2008, 7:260-266.
31. Kim J.K., Carmody I.C., Cohen A.J., Loss G.E. Donor transmission of malignant melanoma to a liver graft recipient: case report and literature review. Clin Transpl 2009, 23:571-574.
32. Kakar S., Burgart L.J., Charlton M.R., Saito Y., Halling K., Thibodeau S.N. Origin of adenocarcinoma in a transplanted liver determined by microsatellite analysis. Hum Pathol 2002, 33:435-436.
33. Marsh J.W., Dvorchik I. Liver organ allocation for hepatocellular carcinoma: are we sure?. Liver Transpl 2003, 9:693-696.
34. Onaca N., Davis G.L., Goldstein R.M., Jennings L.W., Klintmalm G.B. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007, 13:391-399.
35. Duffy J.P., Vardanian A., Benjamin E., et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007, 246:502-509.
36. Yao F.Y., Xiao L., Bass N.M., Kerlan R., Ascher N.L., Roberts J.P. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007, 7:2587-2596.
37. Mazzaferro V., Llovet J.M., Miceli R., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10:35-43.
38. Bismuth H., Castaing D., Ericzon B.G., et al. Hepatic transplantation in Europe. First Report of the European Liver Transplant Registry. Lancet 1987, 2:674-676.
39. Iwatsuki S., Todo S., Marsh J.W., et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998, 187:358-364.
40. De V.I., Steers J.L., Burch P.A., et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000, 6:309-316.
41. Robles R., Figueras J., Turrion V.S., et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg 2004, 239:265-271.
42. Rea D.J., Heimbach J.K., Rosen C.B., et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005, 242:451-458.
43. Frezza E.E., Fung J.J., van Thiel D.H. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997, 44:1172-1181.
44. Jain A.B., Yee L.D., Nalesnik M.A., et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998, 66:1193-1200.
45. Saigal S., Norris S., Muiesan P., Rela M., Heaton N., O'Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 2002, 8:482-487.
46. Sanchez E.Q., Marubashi S., Jung G., et al. De novo tumors after liver transplantation: a single-institution experience. Liver Transpl 2002, 8:285-291.
47. Yao F.Y., Gautam M., Palese C., et al. De novo malignancies following liver transplantation: a case-control study with long-term follow-up. Clin Transpl 2006, 20:617-623.